A prospective study to evaluate the efficacy of proactive management in infantile atopic dermatitis for prevention of sensitization to house dust mite and atopic march

A prospective study to evaluate the efficacy of proactive management in infantile atopic dermatitis for prevention of sensitization to house dust mite and atopic march - A prospective study to evaluate the efficacy of proactive management for prevention of atopic march

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006876

Enrollment

Registered

2012-01-01

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

A proactive approach by using topical corticosteroids (i.e. twice-a-week) to all previously identified affected areas with confirmation of no exacerbation. At exacerbation, patients apply topical co

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients are boys and girls aged 3 to 24 months with a diagnosis of atopic dermatitis or infantile eczema.

Exclusion criteria

Exclusion criteria: The exclusion criteria is as followed; (1) The patients receiving any additional systemic therapies included corticosteroids, nonsteroidal immunosuppressive agents or biological immunotherapy, (2) the patients who has a past history of cardiovascular disease, liver dysfunction, kidney disease and other current serious medical problems.

Design outcomes

Primary

Measure	Time frame
House dust mite specific IgE and house dust mite specific lymphocyte stimulation test [Time Frame: 24 months]	—

Secondary

Measure	Time frame
Japanese cedar pollen specific IgE and specific lymphocyte stimulation test [Time Frame: 24 months]	—

Countries

Japan

Contacts

Public ContactTatsuki Fukuie

Hamamatsu University School of Medicine Department of Pediatrics

fukuie-t@hama-med.ac.jp053-435-2312

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026